Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection.

Abstract

Cutaneous non-tuberculous mycobacterial (NTM) infections are an emerging infectious disease and require a protracted course of combination antibiotics. Antimicrobial choice is limited by resistance and toxicity. Tedizolid is a new oxazolidinone antibiotic with in vitro activity against some NTM, but its use in the management of extrapulmonary NTM has not been described. We report on the utility of prolonged tedizolid use (8 months), after linezolid intolerance, in combination therapy in a case of difficult Mycobacterium chelonae cutaneous infection. Although tedizolid contributed to clinical remission, it may have also contributed to a multifocal peripheral neuropathy. Its efficacy may also have been limited by continued immunosuppression, with evidence to suggest disease relapse or treatment failure after completion of combination therapy. Tedizolid can be considered, with caution, in combination therapy for difficult cases of cutaneous NTM infection.

• Authors: Timothy David Shaw, Mark Smyth, Graham Turner, Michael Hunter
• Journal: Journal of clinical tuberculosis and other mycobacterial diseases (J Clin Tuberc Other Mycobact Dis) Vol. 24 Pg. 100261 (Aug 2021) ISSN: 2405-5794 [Electronic] England
• PMID: 34355067 (Publication Type: Case Reports)
• Copyright: © 2021 The Authors.